Syqe Medical launched the world's first pharmaceutical-grade metered-dose cannabis inhaler in Israel.
The eight years of research and development including rigorous testing through multiple clinical trials paved a novel regulatory path.
This launch marks the beginning of a new chapter in pain treatment, one in which physicians can confidently prescribe precise dosages of cannabis.
The Syqe Inhaler eliminates uncertainty surrounding dosage administration and alleviates physician concerns with regards to adverse events and psychoactivity.
The device has received the first-ever regulatory approval from the Israeli Ministry of Health, and it will be available in the market for only licensed patients in Israel.
This device will enable greater physician adoption of medical cannabis. It introduces complex respiration technique automation, electronic selective dosing and remote clinical monitoring and dose control, along with improved applicability of the cannabis.
Syqe's cannabis inhaler will be marketed and distributed by Teva Israel. The device is produced under controlled pharmaceutical conditions, with Good Manufacturing Practices (GMP).